With 2021 already in the rear-view mirror, Westlake Omics kicks off its 3rd year that starts with a staggering array of encouraging news: an increasingly clarified strategic vision agreed upon in the biotech community; an ever-growing team staffed by highly-motivated and talented individuals from diverse backgrounds; strategic MoUs with big names in the industry; the exclusive distributor and service provider of Pressure BioSciences Inc in China; close collaborations with over 70 top hospitals, research institutes, and pharmaceutical companies throughout the world; as well as widely-acknowledged accolades honored at the “2021 Venture 50”, “Company of the Year” in bioinformatics by Qbitai, and “High-tech Enterprise of Zhejiang Province”. The list goes on and on.
Another big push came on January 13, 2022 when Westlake Omics completed the Pre-A round financing worth hundreds of millions of RMB. Our proved track records of technological capabilities and business know-how keep attracting new investors such as Efung, Med-Fine and XHVC while boosting the confidence from previous partners such as GL Ventures and Gaorong Capital, leading to increased investment. Confidence and support from those household names in the investment community, especially at the bio-pharmaceutical sector, assured us the horizon down the road.
In an era defined by the integration of infotech and biotech, Westlake Omics, a micro world data company that focuses on proteomics, never ceases to believe that our vision, focus, and assiduousness can make a difference to ourselves, and to the world.